Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists

---

Copy For Citation

Babaoglu M., Bayar B., Aynacioglu A., Kerb R., Abali H., Celik I., ...More

CLINICAL PHARMACOLOGY & THERAPEUTICS, vol.78, no.6, pp.619-626, 2005 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 78 Issue: 6
• Publication Date: 2005
• Doi Number: 10.1016/j.clpt.2005.08.015
• Journal Name: CLINICAL PHARMACOLOGY & THERAPEUTICS
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.619-626
• Hacettepe University Affiliated: Yes

Abstract

Background: Resistance to antiemetic treatment with 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists is still a major problem resulting in patient discomfort and poor compliance to chemotherapy. We hypothesized that clinical resistance to 5-HT3 antagonists is associated with the single-nucleotide polymorphism (3435C > T) in the gene that codes for the drug efflux transporter adenosine triphosphate-binding cassette subfamily B member 1 (A-BCB1).